Terumo Corporation (TYO: 4543)
Market Cap | 4.48T |
Revenue (ttm) | 986.67B |
Net Income (ttm) | 119.49B |
Shares Out | 1.48B |
EPS (ttm) | 80.41 |
PE Ratio | 37.64 |
Forward PE | 30.82 |
Dividend | 26.00 (0.85%) |
Ex-Dividend Date | Mar 28, 2025 |
Volume | 2,971,000 |
Open | 3,046.00 |
Previous Close | 3,046.00 |
Day's Range | 3,017.00 - 3,050.00 |
52-Week Range | 2,134.00 - 3,182.00 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 13, 2025 |
About Terumo
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound... [Read more]
Financial Performance
In 2023, Terumo's revenue was 921.86 billion, an increase of 12.39% compared to the previous year's 820.21 billion. Earnings were 106.37 billion, an increase of 19.09%.
Financial StatementsNews
Terumo Corporation (TRUMF) Q2 2025 Earnings Call Transcript
Terumo Corporation (OTCPK:TRUMF) Q2 2025 Earnings Conference Call November 7, 2024 3:00 AM ET Company Participants Jin Hagimoto – Chief Financial Officer Hikaru Samejima – Chief Executive Officer Conf...
Q2 2025 Terumo Corp Earnings Presentation Transcript
Q2 2025 Terumo Corp Earnings Presentation Transcript
Terumo Is a Great Choice for 'Trend' Investors, Here's Why
Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets
Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Easter...
Q1 2025 Terumo Corp Earnings Presentation Transcript
Q1 2025 Terumo Corp Earnings Presentation Transcript
Terumo Corporation (TRUMY) Q4 2024 Earnings Call Transcript
Terumo Corporation (OTCPK:TRUMY) Q4 2024 Results Conference Call May 14, 2024 4:30 AM ET Company Participants Jin Hagimoto - CFO Hikaru Samejima - President, CEO & Director Jin Hagimoto I'm Hagimoto, ...
Terumo Corporation (TRUMF) Q3 2024 Earnings Call Transcript
Terumo Corporation (TRUMF) Q3 2024 Earnings Call Transcript
Terumo Corporation (TRUMF) Q2 2024 Earnings Call Transcript
Terumo Corporation (OTCPK:TRUMF) Q2 2024 Earnings Conference Call November 15, 2023 6:00 AM ET Company Participants Naoki Muto - Chief Accounting Officer & Chief Financial Officer Shinjiro Sato - Chie...
IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium
Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense IceCure joined its exclusive regional distributor, Terumo...
Terumo Corporation (TRUMF) Q1 2024 Earnings Call Transcript
Terumo Corporation (OTCPK:TRUMF) Q1 2024 Earnings Conference Call August 9, 2023 4:15 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer and Group Executive Officer Confere...
Terumo Corporation (TRUMF) Q4 2023 Earnings Call Transcript
Terumo Corporation (OTCPK:TRUMF) Q4 2023 Results Conference Call May 15, 2023 4:30 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer Antoinette Gawin - President & Chief E...
Terumo Corporation (TRUMF) Q3 2023 Earnings Call Transcript
Terumo Corporation (OTCPK:TRUMF) Q3 2023 Earnings Conference Call February 9, 2023 3:00 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer Conference Call Participants Naok...
Terumo Corporation A. (TRUMF) Q2 2022 Earnings Call Transcript
Terumo Corporation A. (OTCPK:TRUMF) Q2 2022 Earnings Conference Call November 10, 2022 7:00 AM ET Company Participants Shinjiro Sato - President & Chief Executive Officer Naoki Muto - Chief Accounting...
Terumo Corporation's (TRUMF) Q1 2022 Results - Earnings Call Transcript
Terumo Corporation (OTCPK:TRUMF) Q1 202 Earnings Conference Call August 9, 2022 4:00 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer Conference Call Participants Naoki M...
Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q4 2021 Results - Earnings Call Transcript
Terumo Corporation (OTCPK:TRUMF) Q4 2021 Earnings Conference Call May 13, 2022 7:00 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer Shinjiro Sato - President and CEO Con...
Terumo Corporation (TRUMF) Q3 2021 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) Q3 2021 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q2 2022 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q2 2022 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) Q1 2022 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) Q1 2022 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) Management on Q3 2021 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) Management on Q3 2021 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) CEO Naoki Muto on Q1 2021 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) CEO Naoki Muto on Q1 2021 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q4 2020 Results - Earnings Call Transcript
Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q4 2020 Results - Earnings Call Transcript
FDA grants emergency authorization to two blood purification systems
The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.